In:
Pulmonary Circulation, Wiley, Vol. 7, No. 3 ( 2017-07), p. 598-608
Abstract:
Therapies that target the prostacyclin pathway are considered effective, yet are complex to dose and may cause dose‐limiting side effects for patients with pulmonary arterial hypertension (PAH). Careful side effect management and the ability to discern side effects from worsening disease are essential in order for patients to continue, and benefit from, prostacyclin therapy. This manuscript was developed through a collaborative effort of allied health providers with extensive experience in managing patients with PAH who are treated with medications that target the prostacyclin pathway. This article provides an overview of individual prostacyclin pathway therapies approved in the United States, side effects most commonly associated with these therapies, and practical suggestions for side effect management. Most patients will experience significant side effects on prostacyclin therapy. Creating a proactive and careful side effect management program will increase the likelihood that patients are able to stay on therapy and receive the benefits afforded by prostacyclin therapy.
Type of Medium:
Online Resource
ISSN:
2045-8940
,
2045-8940
DOI:
10.1177/2045893217719250
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2638089-4
